Nasdaq Tpst News Today

BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...

HC Wainwright restated their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $47.00 price objective on the stock. HC Wainwright also issued estimates for Tempest Therapeutics’ Q1 2024 earnings at ($0.36) EPS, Q2 2024 earnings at ($0.36) […]

Tempest Therapeutics (NASDAQ:TPST – Free Report) had its price target lifted by HC Wainwright from $35.00 to $47.00 in a report published on Wednesday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the stock. Tempest Therapeutics Trading Down 8.5 % TPST opened at $3.64 on Wednesday. The stock has a market capitalization […]

Tempest Therapeutics (NASDAQ:TPST – Get Free Report) had its price target lifted by research analysts at HC Wainwright from $35.00 to $47.00 in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. Tempest Therapeutics Stock Down 59.3 % Shares of TPST stock opened at […]

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 85,000 shares, an increase of 161.5% from the August 31st total of 32,500 shares. Based on an average trading volume of 138,900 shares, the days-to-cover ratio […]

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) saw a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 14,200 shares, a drop of 58.6% from the July 31st total of 34,300 shares. Currently, 0.2% of the company’s stock are short sold. Based on an […]

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 25,800 shares, a drop of 39.3% from the June 15th total of 42,500 shares. Approximately 0.5% of the company’s shares are short sold. […]

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totalling 77,900 shares, a growth of 144.2% from the April 30th total of 31,900 shares. Based on an average daily trading volume, of 238,100 shares, the days-to-cover ratio […]

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 77,900 shares, a growth of 144.2% from the April 30th total of 31,900 shares. Based on an average daily volume of 238,100 shares, the short-interest ratio is currently 0.3 days. […]

BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...